世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Human Coagulation Factor VIII - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Human Coagulation Factor VIII was estimated to be worth US$ 11550 million in 2024 and is forecast to a readjusted size of US$ 17610 million by 2031 with a CAGR of 6.3% during ... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global market for Human Coagulation Factor VIII was estimated to be worth US$ 11550 million in 2024 and is forecast to a readjusted size of US$ 17610 million by 2031 with a CAGR of 6.3% during the forecast period 2025-2031.Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis. Market Drivers: The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape. Market Challenges: Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market. This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Coagulation Factor VIII by region & country, by Type, and by Application. The Human Coagulation Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Bottles) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII. Market Segmentation By Company Takeda Bayer CSL Pfizer Grifols Biogen Octapharma NovoNordisk Greencross Kedrion BPL Hualan Bio RAAS SinoCellTech Taibang Bio Huarun Boya Shuanglin Bio Yuandashuyang Weiguang Bio Segment by Type Recombinant Factor VIII Plasma-derived Factor VIII Segment by Application Hemophilia A Spontanous / Trauma Surgical Other By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Europe Germany France U.K. Italy Netherlands Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Sales, revenue of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Sales, revenue of Human Coagulation Factor VIII in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Table of Contents1 Market Overview1.1 Human Coagulation Factor VIII Product Introduction 1.2 Global Human Coagulation Factor VIII Market Size Forecast 1.2.1 Global Human Coagulation Factor VIII Sales Value (2020-2031) 1.2.2 Global Human Coagulation Factor VIII Sales Volume (2020-2031) 1.2.3 Global Human Coagulation Factor VIII Sales Price (2020-2031) 1.3 Human Coagulation Factor VIII Market Trends & Drivers 1.3.1 Human Coagulation Factor VIII Industry Trends 1.3.2 Human Coagulation Factor VIII Market Drivers & Opportunity 1.3.3 Human Coagulation Factor VIII Market Challenges 1.3.4 Human Coagulation Factor VIII Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Human Coagulation Factor VIII Players Revenue Ranking (2024) 2.2 Global Human Coagulation Factor VIII Revenue by Company (2020-2025) 2.3 Global Human Coagulation Factor VIII Players Sales Volume Ranking (2024) 2.4 Global Human Coagulation Factor VIII Sales Volume by Company Players (2020-2025) 2.5 Global Human Coagulation Factor VIII Average Price by Company (2020-2025) 2.6 Key Manufacturers Human Coagulation Factor VIII Manufacturing Base and Headquarters 2.7 Key Manufacturers Human Coagulation Factor VIII Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Human Coagulation Factor VIII 2.9 Human Coagulation Factor VIII Market Competitive Analysis 2.9.1 Human Coagulation Factor VIII Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Human Coagulation Factor VIII Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Coagulation Factor VIII as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Recombinant Factor VIII 3.1.2 Plasma-derived Factor VIII 3.2 Global Human Coagulation Factor VIII Sales Value by Type 3.2.1 Global Human Coagulation Factor VIII Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Human Coagulation Factor VIII Sales Value, by Type (2020-2031) 3.2.3 Global Human Coagulation Factor VIII Sales Value, by Type (%) (2020-2031) 3.3 Global Human Coagulation Factor VIII Sales Volume by Type 3.3.1 Global Human Coagulation Factor VIII Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Human Coagulation Factor VIII Sales Volume, by Type (2020-2031) 3.3.3 Global Human Coagulation Factor VIII Sales Volume, by Type (%) (2020-2031) 3.4 Global Human Coagulation Factor VIII Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hemophilia A 4.1.2 Spontanous / Trauma 4.1.3 Surgical 4.1.4 Other 4.2 Global Human Coagulation Factor VIII Sales Value by Application 4.2.1 Global Human Coagulation Factor VIII Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Human Coagulation Factor VIII Sales Value, by Application (2020-2031) 4.2.3 Global Human Coagulation Factor VIII Sales Value, by Application (%) (2020-2031) 4.3 Global Human Coagulation Factor VIII Sales Volume by Application 4.3.1 Global Human Coagulation Factor VIII Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Human Coagulation Factor VIII Sales Volume, by Application (2020-2031) 4.3.3 Global Human Coagulation Factor VIII Sales Volume, by Application (%) (2020-2031) 4.4 Global Human Coagulation Factor VIII Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Human Coagulation Factor VIII Sales Value by Region 5.1.1 Global Human Coagulation Factor VIII Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Human Coagulation Factor VIII Sales Value by Region (2020-2025) 5.1.3 Global Human Coagulation Factor VIII Sales Value by Region (2026-2031) 5.1.4 Global Human Coagulation Factor VIII Sales Value by Region (%), (2020-2031) 5.2 Global Human Coagulation Factor VIII Sales Volume by Region 5.2.1 Global Human Coagulation Factor VIII Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Human Coagulation Factor VIII Sales Volume by Region (2020-2025) 5.2.3 Global Human Coagulation Factor VIII Sales Volume by Region (2026-2031) 5.2.4 Global Human Coagulation Factor VIII Sales Volume by Region (%), (2020-2031) 5.3 Global Human Coagulation Factor VIII Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Human Coagulation Factor VIII Sales Value, 2020-2031 5.4.2 North America Human Coagulation Factor VIII Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Human Coagulation Factor VIII Sales Value, 2020-2031 5.5.2 Europe Human Coagulation Factor VIII Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Human Coagulation Factor VIII Sales Value, 2020-2031 5.6.2 Asia Pacific Human Coagulation Factor VIII Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Human Coagulation Factor VIII Sales Value, 2020-2031 5.7.2 South America Human Coagulation Factor VIII Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Human Coagulation Factor VIII Sales Value, 2020-2031 5.8.2 Middle East & Africa Human Coagulation Factor VIII Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Human Coagulation Factor VIII Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Human Coagulation Factor VIII Sales Value and Sales Volume 6.2.1 Key Countries/Regions Human Coagulation Factor VIII Sales Value, 2020-2031 6.2.2 Key Countries/Regions Human Coagulation Factor VIII Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Human Coagulation Factor VIII Sales Value, 2020-2031 6.3.2 United States Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Human Coagulation Factor VIII Sales Value, 2020-2031 6.4.2 Europe Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Human Coagulation Factor VIII Sales Value, 2020-2031 6.5.2 China Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.5.3 China Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Human Coagulation Factor VIII Sales Value, 2020-2031 6.6.2 Japan Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Human Coagulation Factor VIII Sales Value, 2020-2031 6.7.2 South Korea Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Human Coagulation Factor VIII Sales Value, 2020-2031 6.8.2 Southeast Asia Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Human Coagulation Factor VIII Sales Value, 2020-2031 6.9.2 India Human Coagulation Factor VIII Sales Value by Type (%), 2024 VS 2031 6.9.3 India Human Coagulation Factor VIII Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Takeda 7.1.1 Takeda Company Information 7.1.2 Takeda Introduction and Business Overview 7.1.3 Takeda Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 Takeda Human Coagulation Factor VIII Product Offerings 7.1.5 Takeda Recent Development 7.2 Bayer 7.2.1 Bayer Company Information 7.2.2 Bayer Introduction and Business Overview 7.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Bayer Human Coagulation Factor VIII Product Offerings 7.2.5 Bayer Recent Development 7.3 CSL 7.3.1 CSL Company Information 7.3.2 CSL Introduction and Business Overview 7.3.3 CSL Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 CSL Human Coagulation Factor VIII Product Offerings 7.3.5 CSL Recent Development 7.4 Pfizer 7.4.1 Pfizer Company Information 7.4.2 Pfizer Introduction and Business Overview 7.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Pfizer Human Coagulation Factor VIII Product Offerings 7.4.5 Pfizer Recent Development 7.5 Grifols 7.5.1 Grifols Company Information 7.5.2 Grifols Introduction and Business Overview 7.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Grifols Human Coagulation Factor VIII Product Offerings 7.5.5 Grifols Recent Development 7.6 Biogen 7.6.1 Biogen Company Information 7.6.2 Biogen Introduction and Business Overview 7.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Biogen Human Coagulation Factor VIII Product Offerings 7.6.5 Biogen Recent Development 7.7 Octapharma 7.7.1 Octapharma Company Information 7.7.2 Octapharma Introduction and Business Overview 7.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Octapharma Human Coagulation Factor VIII Product Offerings 7.7.5 Octapharma Recent Development 7.8 NovoNordisk 7.8.1 NovoNordisk Company Information 7.8.2 NovoNordisk Introduction and Business Overview 7.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 NovoNordisk Human Coagulation Factor VIII Product Offerings 7.8.5 NovoNordisk Recent Development 7.9 Greencross 7.9.1 Greencross Company Information 7.9.2 Greencross Introduction and Business Overview 7.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Greencross Human Coagulation Factor VIII Product Offerings 7.9.5 Greencross Recent Development 7.10 Kedrion 7.10.1 Kedrion Company Information 7.10.2 Kedrion Introduction and Business Overview 7.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 Kedrion Human Coagulation Factor VIII Product Offerings 7.10.5 Kedrion Recent Development 7.11 BPL 7.11.1 BPL Company Information 7.11.2 BPL Introduction and Business Overview 7.11.3 BPL Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 BPL Human Coagulation Factor VIII Product Offerings 7.11.5 BPL Recent Development 7.12 Hualan Bio 7.12.1 Hualan Bio Company Information 7.12.2 Hualan Bio Introduction and Business Overview 7.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Hualan Bio Human Coagulation Factor VIII Product Offerings 7.12.5 Hualan Bio Recent Development 7.13 RAAS 7.13.1 RAAS Company Information 7.13.2 RAAS Introduction and Business Overview 7.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 RAAS Human Coagulation Factor VIII Product Offerings 7.13.5 RAAS Recent Development 7.14 SinoCellTech 7.14.1 SinoCellTech Company Information 7.14.2 SinoCellTech Introduction and Business Overview 7.14.3 SinoCellTech Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 SinoCellTech Human Coagulation Factor VIII Product Offerings 7.14.5 SinoCellTech Recent Development 7.15 Taibang Bio 7.15.1 Taibang Bio Company Information 7.15.2 Taibang Bio Introduction and Business Overview 7.15.3 Taibang Bio Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Taibang Bio Human Coagulation Factor VIII Product Offerings 7.15.5 Taibang Bio Recent Development 7.16 Huarun Boya 7.16.1 Huarun Boya Company Information 7.16.2 Huarun Boya Introduction and Business Overview 7.16.3 Huarun Boya Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.16.4 Huarun Boya Human Coagulation Factor VIII Product Offerings 7.16.5 Huarun Boya Recent Development 7.17 Shuanglin Bio 7.17.1 Shuanglin Bio Company Information 7.17.2 Shuanglin Bio Introduction and Business Overview 7.17.3 Shuanglin Bio Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.17.4 Shuanglin Bio Human Coagulation Factor VIII Product Offerings 7.17.5 Shuanglin Bio Recent Development 7.18 Yuandashuyang 7.18.1 Yuandashuyang Company Information 7.18.2 Yuandashuyang Introduction and Business Overview 7.18.3 Yuandashuyang Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.18.4 Yuandashuyang Human Coagulation Factor VIII Product Offerings 7.18.5 Yuandashuyang Recent Development 7.19 Weiguang Bio 7.19.1 Weiguang Bio Company Information 7.19.2 Weiguang Bio Introduction and Business Overview 7.19.3 Weiguang Bio Human Coagulation Factor VIII Sales, Revenue, Price and Gross Margin (2020-2025) 7.19.4 Weiguang Bio Human Coagulation Factor VIII Product Offerings 7.19.5 Weiguang Bio Recent Development 8 Industry Chain Analysis 8.1 Human Coagulation Factor VIII Industrial Chain 8.2 Human Coagulation Factor VIII Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Human Coagulation Factor VIII Sales Model 8.5.2 Sales Channel 8.5.3 Human Coagulation Factor VIII Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（coagulation factor）の最新刊レポートよくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
